BI
Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)
₹29.37
Mkt cap
₹48 Cr
P/E ratio
91.90
P/B
2.19
Div yield
0.00%
ROE
−2.83%
ROCE
2.97%
EPS (TTM)
₹0.32
Book value
₹13
52W range
26–46
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd deals in Pharmaceuticals and Chemicals products. [1]
NSE BIOFILCHEMBSE 524396
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−36.62% from high₹29
₹26+14.73% from low₹46
Current
₹29.37
Prev close
₹30.26
Day
−2.94%
Price performance
1D
−3.04%
1W
−6.53%
1M
+1.03%
3M
−4.68%
6M
−7.00%
1Y
−25.21%
YTD
−12.30%
Financials
Revenue, profit & margin
P/E ratio
91.9×
BIOFILCHEM is 183% above the sector median of 32.5×
BIOFILCHEM91.9×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.37 | 5.03 | 15.20 | 8.44 | 2.41 | 14.20 | 8.35 | 6.43 | 13.54 | 0.86 | 7.57 | 12.35 | 1.67 | |
| YoY Sales growth | +562.98% | +237.58% | +11.60% | +247.33% | -86.13% | +182.31% | -45.07% | -23.82% | +461.83% | -93.94% | -9.34% | +92.07% | -87.67% | |
| Expenses | 17.13 | 4.84 | 15.24 | 8.13 | 2.29 | 13.89 | 8.24 | 6.42 | 13.42 | 0.77 | 7.14 | 12.21 | 1.57 | |
| Operating Profit | 0.24 | 0.19 | -0.04 | 0.31 | 0.12 | 0.31 | 0.11 | 0.01 | 0.12 | 0.09 | 0.43 | 0.14 | 0.10 | |
| OPM % | 1.38% | 3.78% | -0.26% | 3.67% | 4.98% | 2.18% | 1.32% | 0.16% | 0.89% | 10.47% | 5.68% | 1.13% | 5.99% | |
| Other Income | 0.03 | 0.03 | 0.41 | 0.03 | 0.02 | 0.02 | 0.24 | 2.83 | 0.06 | 0.08 | 0.11 | 0.06 | 0.13 | |
| Interest | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Depreciation | 0.11 | 0.11 | 0.08 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Profit before tax | 0.15 | 0.11 | 0.27 | 0.23 | 0.03 | 0.22 | 0.26 | 2.76 | 0.11 | 0.10 | 0.47 | 0.13 | 0.15 | |
| Tax % | 20.00% | 18.18% | 11.11% | 26.09% | 33.33% | 27.27% | 23.08% | 12.68% | 27.27% | 30.00% | 55.32% | 23.08% | 26.67% | |
| Net Profit | 0.12 | 0.09 | 0.25 | 0.17 | 0.02 | 0.16 | 0.20 | 2.41 | 0.08 | 0.08 | 0.21 | 0.11 | 0.12 | |
| EPS in Rs | 0.07 | 0.06 | 0.15 | 0.10 | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 | 0.07 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.09% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26◦ |
| Earnings day | +0.09% |
| +1 day | −2.57% |
| +5 days | −5.30% |
| +15 days | −2.11% |
| +30 days | −0.95% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202646.79%Promoter
Promoters46.79%
FIIs0.00%
DIIs0.08%
Public53.13%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Biofil Chemicals | ₹29.37 | 91.88 | 48 | 0.00% | 0 | +50.00% | 2 | −87.67% | 2.97% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov - Submission of publication of Un-audited financial results in the Newspaper pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015.To Review, Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report. 14 Nov - Board approved Q2 FY26 results; manufacturing facility upgradation expected in 3-6 months.Board Meeting Outcome for Board Meeting Outcome To Review, Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report 14 Nov - Q2 FY27 results: PAT Rs 11.53 lakh, board approved on 14 Nov 2026; facility upgradation in 3-6 months.Board Meeting Intimation for For Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th
September, 2026 Along With Limited Review Report Thereon. 3 Nov - Board to meet on 14 Nov 2026 to approve Q2/H1 FY27 unaudited results; trading window remains closed.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended 30th September, 2026






